Desiree: dose escalation of everolimus published
18.11.2022
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
A dose-escalation schema of everolimus over 3 weeks can be successfully used to reduce the incidence of high-grade stomatitis in the first 12 weeks of treatment in patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.“
- Article link: https://authors.elsevier.com/sd/article/S2059702922002319 (Open Access)
News
-
28.09.2023 Translational Work from GeparSepto published
The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
Mehr ... -
27.09.2023 GBG research at SABCS
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
Mehr ... -
21.09.2023 New review on Immune Cell Infiltration published
A review from the International Immuno-Oncology Biomarker Working about tumor immunology was published in the journal of pathology.
Mehr ... -
07.09.2023 Save the date! GBG Annual Scientific Meeting 2024
Das 21. Annual Scientific Meeting 2024 wird am 29.2. bis 1.3. in Frankfurt stattfinden.
Mehr ...